The Role of American Thyroid Association Pediatric Thyroid Cancer Risk Stratification and <i>BRAF<SUP>V600E</SUP></i> Mutation in Predicting the Response to Treatment in Papillary Thyroid Cancer Patients ≤18 Years Old

Creative Commons License

Giles Senyurek Y., Iscan Y., Sormaz İ. C., Poyrazoglu Ş., Tunca F.

JOURNAL OF CLINICAL RESEARCH IN PEDIATRIC ENDOCRINOLOGY, cilt.14, sa.2, ss.196-206, 2022 (SCI-Expanded) identifier identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 14 Sayı: 2
  • Basım Tarihi: 2022
  • Doi Numarası: 10.4274/jcrpe.galenos.2022.2021-10-4
  • Dergi Adı: JOURNAL OF CLINICAL RESEARCH IN PEDIATRIC ENDOCRINOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CINAHL, EMBASE, MEDLINE, Directory of Open Access Journals, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.196-206
  • Anahtar Kelimeler: BRAF(V600E) mutation, dynamic risk stratification, pediatric thyroid cancer, thyroid cancer, MANAGEMENT GUIDELINES, BRAF MUTATION, CHILDREN, RECURRENCE, ADOLESCENTS, CHILDHOOD, CARCINOMA, FEATURES, REMISSION, PROGNOSIS
  • İstanbul Üniversitesi Adresli: Evet

Özet

Objective: This study aimed to evaluate the role of risk stratification by the American Thyroid Association (ATA) pediatric thyroid cancer risk levels and BRAF(V600E) mutation to predict the response to treatment in papillary thyroid cancer (PTC) patients <= 18 years old. Methods: Clinical outcomes during a median period of 6 (2-21.8) years were assessed in 70 patients, according to ATA pediatric risk stratification, BRAF(V600E) mutation status, and dynamic risk stratification (DRS) at final follow-up. Results: Of 70 patients, 44 (63%), 14 (20%), and 12 (17%) were classified initially as low-, intermediate-, and high-risk, respectively. BRAF(V600E) mutation analysis data was available in 55 (78.6%) patients, of whom 18 (32.7%) had the BRAF(V600E) mutation. According to the final DRS, 61 (87%), two (3%), six (9%), and one (1%) patients were classified as an excellent, incomplete biochemical, incomplete structural, and indeterminate response, respectively. All ATA low-risk patients showed excellent response to treatment, whereas the rate of excellent response was 65.4% in intermediate-and high-risk levels (p<0.001). The rates of excellent response in BRAF(V600E) positive and negative patients were 83% and 92%, respectively (p=0.339). The rate of locoregional recurrence was significantly higher in BRAF(V600E) positive vs negative patients (33.3% vs 2.7% respectively, p=0.001). Conclusion: ATA pediatric risk stratification is effective in predicting response to treatment in PTC patients <= 18 years old. The presence of BRAF(V600E) mutation was highly predictive for recurrence but had no significant impact on the rate of excellent response to treatment at final follow-up.